Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma

Journal of Immunology

Volumn 174, Issue 3, 2005, Pages 1709-1716

  Bricard, Gabriel ^a   Bouzourene, Hanifa ^b   Martinet, Olivier ^c,e   Rimoldi, Donata ^d   Halkic, Nermin ^c   Gillet, Michel ^c   Chaubert, Pascal ^b   MacDonald, H Robson ^d   Romero, Pedro ^a   Cerottini, Jean Charles ^a,d   Speiser, Daniel E ^a,f  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^f Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER TESTIS ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA A ANTIGEN; RNA; TUMOR ANTIGEN; TUMOR PROTEIN;

AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 19944432610     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.3.1709     Document Type: Article

References (45)

1. Schwartz, J. D., M. Schwartz, J. Mandeli, and M. Sung. 2002. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 3:593.
2. Di Maio, M., E. De Maio, F. Perrone, S. Pignata, and B. Daniele. 2002. Hepatocellular carcinoma: systemic treatments. J. Clin. Gastroenterol. 35:S109.
3. Llovet, J. M., M. Sala, L. Castells, Y. Suarez, R. Vilana, L. Bianchi, C. Ayuso, V. Vargas, J. Rodes, and J. Bruix. 2000. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31:54.
4. Ikeda, K., Y. Arase, S. Saitoh, M. Kobayashi, Y. Suzuki, F. Suzuki, A. Tsubota, K. Chayama, N. Murashima, and H. Kumada. 2000. Interferon β prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228.
5. Ladhams, A., C. Schmidt, G. Sing, L. Butterworth, G. Fielding, P. Tesar, R. Strong, B. Leggett, L. Powell, G. Maddern, et al. 2002. Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J. Gastroenterol. Hepatol. 17:889.
6. Takayama, T., T. Sekine, M. Makuuchi, S. Yamasaki, T. Kosuge, J. Yamamoto, K. Shimada, M. Sakamoto, S. Hirohashi, Y. Ohashi, and T. Kakizoe. 2000. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802.
7. Wada, Y., O. Nakashima, R. Kutami, O. Yamamoto, and M. Kojiro. 1998. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology 27:407.
8. Clemente, C. G., M. C. Mihm, Jr., R. Bufalino, S. Zurrida, P. Collini, and N. Cascinelli. 1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303.
9. Zhang, L., J. R. Conejo-Garcia, D. Katsaros, P. A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203.
10. + cells in patients with hepatocellular carcinoma. J. Hepatol. 40:102.
11. Zendman, A. J., D. J. Ruiter, and G. N. Van Muijen. 2003. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell Physiol. 194:272.
12. Van Der Bruggen, P., Y. Zhang, P. Chaux, V. Stroobant, C. Panichelli, E. S. Schultz, J. Chapiro, B. J. Van Den Eynde, F. Brasseur, and T. Boon. 2002. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol. Rev. 188:51.
13. Jassim, A., W. Ollier, A. Payne, A. Biro, R. T. Oliver, and H. Festenstein. 1989. Analysis of HLA antigens on germ cells in human semen. Eur. J. Immunol. 19:1215.
14. Scanlan, M. J., A. O. Gure, A. A. Jungbluth, L. J. Old, and Y. T. Chen. 2002. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188:22.
15. Chen, C. H., G. J. Chen, H. S. Lee, G. T. Huang, P. M. Yang, L. J. Tsai, D. S. Chen, and J. C. Sheu. 2001. Expressions of cancer-testis antigens in human hepatocellular carcinomas. Cancer Lett. 164:189.
16. Luo, G., S. Huang, X. Xie, E. Stockert, Y. T. Chen, B. Kubuschok, and M. Pfreundschuh. 2002. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun. 2:11.
17. Tahara, K., M. Mon, N. Sadanaga, Y. Sakamoto, S. Kitano, and M. Makuuchi. 1999. Expression of the MAGE gene family in human hepatocellular carcinoma. Cancer 85:1234.
18. Kobayashi, Y., T. Higashi, K. Nouso, H. Nakatsukasa, M. Ishizaki, T. Kaneyoshi, N. Toshikuni, K. Kariyama, E. Nakayama, and T. Tsuji. 2000. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J. Hepatol. 32:612.
19. Romero, P., P. R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J. L. Chen, D. Lienard, J. C. Cerottini, and V. Cerundolo. 1998. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1641.
20. Deng, X. L., W. Chen, M. Y. Cai, and D. P. Wei. 2003. Expression of class 1 MHC molecule, HSP70 and TAP in human hepatocellular carcinoma. World J. Gastroenterol. 9:1853.
21. Huang, J., M. Y. Cai, and D. P. Wei. 2002. HLA class I expression in primary hepatocellular carcinoma. World J. Gastroenterol. 8:654.
22. Kurokohchi, K., M. Carrington, D. L. Mann, T. B. Simonis, M. A. Alexander-Miller, S. M. Feinstone, T. Akatsuka, and J. A. Berzofsky. 1996. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 23:1181.
23. 254-262 in melanoma. Cancer Res. 61:509.
24. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60:4499.
25. + T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Cancer Res. 63:5601.
26. Rimoldi, D., V. Rubio-Godoy, V. Dutoit, D. Lienard, S. Salvi, P. Guillaume, D. Speiser, E. Stockert, G. Spagnoli, C. Servis, et al. 2000. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J. Immunol 165:7253.
27. Rimoldi, D., S. Salvi, D. Reed, P. Coulie, V. C. Jongeneel, E. De Plaen, F. Brasseur, A. M. Rodriguez, T. Boon, and J. C. Cerottini. 1999. cDNA and protein characterization of human MAGE-10. Int. J. Cancer 82:901.
28. Gure, A. O., O. Tureci, U. Sahin, S. Tsang, M. J. Scanlan, E. Jager, A. Knuth, M. Pfreundschuh, L. J. Old, and Y. T. Chen. 1997. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int. J. Cancer 72:965.
29. Lethe, B., S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen, and T. Boon. 1998. LAGE-I, a new gene with tumor specificity. Int. J. Cancer 76:903.
30. + T-cell response to NY-ESO-I: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin. Cancer Res. 7:766s.
31. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
32. De Smet, C., C. Lurquin, B. Lethe, V. Martelange, and T. Boon. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell Biol. 19:7327.
33. dos Santos, N. R., R. Torensma, T. J. de Vries, M. W. Schreurs, D. R. de Bruijn, E. Kater-Baats, D. J. Ruiter, G. J. Adema, G. N. van Muijen, and A. G. van Kessel. 2000. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 60:1654.
34. Jungbluth, A. A., Y. T. Chen, E. Stockert, K. J. Busam, D. Kolb, K. Iversen, K. Coplan, B. Williamson, N. Altorki, and L. J. Old. 2001. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer 92:856.
35. Jungbluth, A. A., E. Stockert, Y. T. Chen, D. Kolb, K. Iversen, K. Coplan, B. Williamson, N. Altorki, K. J. Busam, and L. J. Old. 2000. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br. J. Cancer 83:493.
36. Rimoldi, D., S. Salvi, E. Schultz-Thater, G. C. Spagnoli, and J. C. Cerottini. 2000. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6Cl can be used to study different proteins of the MAGE-A family. Int. J. Cancer. 86:749.
37. Knabel, M., T. J. Franz, M. Schiemann, A. Wulf, B. Villmow, B. Schmidt, H. Bernhard, H. Wagner, and D. H. Busch. 2002. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8:631.
38. Haruna, Y., N. Hayashi, T. Kamada, P. Hytiroglou, S. N. Thung, and M. A. Gerber. 1994. Expression of hepatitis C virus in hepatocellular carcinoma. Cancer 73:2253.
39. Speiser, D. E., D. Kyburz, U. Stubi, H. Hengartner, and R. M. Zinkernagel. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149:972.
40. 254-262: high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61:5850.
41. Dutoit, V., P. Guillaume, J. C. Cerottini, P. Romero, and D. Valmori. 2002. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. Eur. J. Immunol. 32:3285.
42. Speiser, D. E., M. J. Pittet, D. Rimoldi, P. Guillaume, I. F. Luescher, D. Lienard, F. Lejeune, J. C. Cerottini, and P. Romero. 2003. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor specific T cells. Semin. Cancer Biol. 13:461.
43. Fisher, B., B. S. Packard, E. J. Read, J. A. Carrasquillo, C. S. Carter, S. L. Topalian, J. C. Yang, P. Yolles, S. M. Larson, and S. A. Rosenberg. 1989. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7:250.
44. Meidenbauer, N., J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen. 2003. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. 170:2161.
45. Mitchell, M. S., D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell. 2002. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 20:1075.